Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivoryon Therapeutics NVLTS:0R3M +0.84%32 PB Ratio is 7.53 as of Jul. 21, 2026, which is 219% above its 10-year median of 2.36. GuruFocus rates LTS:0R3M with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,229 Biotechnology companies, Vivoryon Therapeutics NV ranks worse than 79.66% on this metric.
Vivoryon Therapeutics NV stock PB Ratio (=7.25) is close to 2-year high of 7.25.
The historical rank and industry rank for Vivoryon Therapeutics NV's PB Ratio or its related term are showing as below:
LTS:0R3M'
s PB Ratio Range Over the Past 10 Years
Min: 0.45 Med: 2.36 Max: 23.12
Current: 7.31
During the past 13 years, Vivoryon Therapeutics NV's highest PB Ratio was 23.12. The lowest was 0.45. And the median was 2.36.
LTS:0R3M's PB Ratio is ranked worse than 79.66% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs LTS:0R3M: 7.31
During the past 12 months, Vivoryon Therapeutics NV's average Book Value Per Share Growth Rate was -47.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -47.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -32.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -14.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vivoryon Therapeutics NV was 77.80% per year. The lowest was -58.90% per year. And the median was -8.40% per year.
Back to Basics: PB Ratio
Vivoryon Therapeutics NV (LTS:0R3M) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vivoryon Therapeutics NV's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivoryon Therapeutics NV PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vivoryon Therapeutics NV's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vivoryon Therapeutics NV (LTS:0R3M) has a PB Ratio of 7.53 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivoryon Therapeutics NV and its competitors. This is 219% above median its historical median of 2.36. Over the past decade, Vivoryon Therapeutics NV's PB Ratio has ranged from 0.45 to 23.12. According to the industry distribution chart, Vivoryon Therapeutics NV ranks #979 out of 1229 companies in the Biotechnology industry, placing it in the top 79.7%.
Is Vivoryon Therapeutics NV's PB Ratio too high?
Vivoryon Therapeutics NV's current PB Ratio of 7.53 is 219% above median its 10-year median of 2.36. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 23.12. The Biotechnology industry median PB Ratio is 2.79. Vivoryon Therapeutics NV's value of 7.53 is 169.9% above this industry median. Based on the distribution chart, Vivoryon Therapeutics NV ranks #979 out of 1229 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vivoryon Therapeutics NV has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivoryon Therapeutics NV ranks #979 out of 1229 companies for PB Ratio. This places Vivoryon Therapeutics NV in the lower half of its industry. The industry median PB Ratio is 2.79. Vivoryon Therapeutics NV's value of 7.53 is 169.9% above this benchmark. Historically, Vivoryon Therapeutics NV's own PB Ratio has ranged from 0.45 to 23.12 over the past decade. While the company's 10-year median is 2.36 vs. the industry median of 2.79, Vivoryon Therapeutics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivoryon Therapeutics NV's current PB Ratio of 7.53 is 169.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivoryon Therapeutics NV and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivoryon Therapeutics NV's current PB Ratio is 7.53, which is 219% above median its own 10-year median of 2.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (LTS:0R3M) has a current PB Ratio of 7.53. The current PB Ratio is 7.53, which is 219% above median its 10-year median of 2.36 and 169.9% above the Biotechnology industry median of 2.79. Vivoryon Therapeutics NV's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vivoryon Therapeutics NV (LTS:0R3M), the current PB Ratio is 7.53 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
32GF Score
Get the complete analysis for LTS:0R3M
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R3M has been successfully added to your 
